Naives, Nonresponders, Relapsers: Who Is There Left to Treat?

Archita Desai, Nancy Reau

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Hepatitis C has a high prevalence in the United States, and the disease burden of HCV will increase over the next 20 to 30 years by many estimates. Trials to evaluate new therapies and optimize the use of triple drug therapies are needed if HCV is to be successfully controlled and its incumbent morbidity and mortality drastically lowered for all groups of patients. With improvements in ability to achieve SVR with agents such as telaprevir and boceprevir, efforts to improve treatment uptake rates and to re-examine the utility of universal or more inclusive screening for chronic hepatitis C are warranted.

Original languageEnglish (US)
Pages (from-to)483-495
Number of pages13
JournalClinics in Liver Disease
Volume15
Issue number3
DOIs
StatePublished - Aug 2011
Externally publishedYes

Fingerprint

Chronic Hepatitis C
Hepatitis C
Morbidity
Drug Therapy
Mortality
Therapeutics
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
telaprevir

Keywords

  • Epidemiology
  • Hepatitis C
  • Non-responders
  • Pegylated interferon
  • Relapse
  • Ribavirin

ASJC Scopus subject areas

  • Hepatology

Cite this

Naives, Nonresponders, Relapsers : Who Is There Left to Treat? / Desai, Archita; Reau, Nancy.

In: Clinics in Liver Disease, Vol. 15, No. 3, 08.2011, p. 483-495.

Research output: Contribution to journalArticle

@article{949ff591ac4e411a91f995f3aa760b29,
title = "Naives, Nonresponders, Relapsers: Who Is There Left to Treat?",
abstract = "Hepatitis C has a high prevalence in the United States, and the disease burden of HCV will increase over the next 20 to 30 years by many estimates. Trials to evaluate new therapies and optimize the use of triple drug therapies are needed if HCV is to be successfully controlled and its incumbent morbidity and mortality drastically lowered for all groups of patients. With improvements in ability to achieve SVR with agents such as telaprevir and boceprevir, efforts to improve treatment uptake rates and to re-examine the utility of universal or more inclusive screening for chronic hepatitis C are warranted.",
keywords = "Epidemiology, Hepatitis C, Non-responders, Pegylated interferon, Relapse, Ribavirin",
author = "Archita Desai and Nancy Reau",
year = "2011",
month = "8",
doi = "10.1016/j.cld.2011.05.011",
language = "English (US)",
volume = "15",
pages = "483--495",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Naives, Nonresponders, Relapsers

T2 - Who Is There Left to Treat?

AU - Desai, Archita

AU - Reau, Nancy

PY - 2011/8

Y1 - 2011/8

N2 - Hepatitis C has a high prevalence in the United States, and the disease burden of HCV will increase over the next 20 to 30 years by many estimates. Trials to evaluate new therapies and optimize the use of triple drug therapies are needed if HCV is to be successfully controlled and its incumbent morbidity and mortality drastically lowered for all groups of patients. With improvements in ability to achieve SVR with agents such as telaprevir and boceprevir, efforts to improve treatment uptake rates and to re-examine the utility of universal or more inclusive screening for chronic hepatitis C are warranted.

AB - Hepatitis C has a high prevalence in the United States, and the disease burden of HCV will increase over the next 20 to 30 years by many estimates. Trials to evaluate new therapies and optimize the use of triple drug therapies are needed if HCV is to be successfully controlled and its incumbent morbidity and mortality drastically lowered for all groups of patients. With improvements in ability to achieve SVR with agents such as telaprevir and boceprevir, efforts to improve treatment uptake rates and to re-examine the utility of universal or more inclusive screening for chronic hepatitis C are warranted.

KW - Epidemiology

KW - Hepatitis C

KW - Non-responders

KW - Pegylated interferon

KW - Relapse

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=80051949697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051949697&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2011.05.011

DO - 10.1016/j.cld.2011.05.011

M3 - Article

C2 - 21867932

AN - SCOPUS:80051949697

VL - 15

SP - 483

EP - 495

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 3

ER -